Characteristic | All patients (n=623, 100%) | Non-small cell lung cancer (n=318, 51.0%) | Melanoma (n=305, 49.0%) |
Sex, n (%) Male Female | 353 (56.7) 270 (43.3) | 201 (63.2) 117 (36.8) | 152 (49.8) 153 (50.2) |
Age (years) Median range | 63 (22–92) | 63 (34–92) | 62 (22–91) |
Immunotherapy, n (%) Pembrolizumab Nivolumab Nivolumab+ipilimumab Durvalumab | 318 (51.0) 286 (45.9) 10 (1.6) 9 (1.4) | 76 (23.9) 233 (73.3) – 9 (2.8) | 242 (79.3) 53 (17.4) 10 (3.3) – |
Stage, n (%) IV III II | 536 (86.0) 85 (13.6) 2 (0.3) | 276 (86.58) 41 (12.9) 1 (0.3) | 260 (85.2) 44 (14.4) 1 (0.3) |
Metastasis Bone Liver Brain | 205 (32.9) 165 (26.5) 183 (29.4) | 144 (45.3) 87 (27.4) 87 (27.4) | 61 (20.0) 78 (25.6) 96 (31.5) |
Prior treatment Systemic Radiotherapy Prior surgery | 431 (69.2) 275 (44.1) 335 (53.7) | 296 (93.1) 165 (51.9) 98 (30.8) | 135 (44.3) 110 (36.1) 237 (77.7) |
Outcome | |||
1-year mortality rate 95% CI Events | 0.496 (0.457 to 0.537) 309 | 0.411 (0.359 to 0.47) 182 | 0.582 (0.529 to 0.64) 127 |
5-year mortality rate 95% CI Events | 0.196 (0.165 to 0.233) 477 | 0.11 (0.0762 to 0.158) 264 | 0.279 (0.23 to 0.337) 213 |
Overall survival (months) Median IQR | 11.8 2.9–37.3 | 8.7 2.1–21.1 | 19.7 5.6–73.3 |
Follow-up (months) Median IQR | 10.7 2.7–32.3 | 7.0 2.0–19.0 | 18.8 5.3–46.8 |
Morphometric data | |||
BMI (kg/m²) Mean (±SD) (min–max) | 24.1 (±4.7) (13.7–41.4) | 23.2 (±4.7) (13.7–39.9) | 25.0 (±4.5) (16.0–41.4) |
FBM (kg/m²) Mean (±SD) (min–max) | 5.7 (±3.5) (0.1–21.9) | 4.9 (±3.2) (0.1–18.3) | 6.6 (±3.6) (0.8–21.9) |
SFM (kg/m²) Mean (±SD) (min–max) | 4.8 (±3.0) (0.1–20.7) | 4.1 (±2.7) (0.1–15.7) | 5.5 (±3.1) (0.8–20.7) |
VFM (kg/m²) Mean (±SD) (min–max) | 0.9 (±0.7) (0.01–3.4) | 0.9 (±0.7) (0.01–3.4) | 1.0 (±0.7) (0.02–3.3) |
MBM (kg/m²) Mean (±SD) (min–max) | 5.8 (±1.5) (1.2–14.1) | 5.4 (±1.4) (1.2–9.9) | 6.2 (±1.6) (2.9–14.1) |
LBM (kg/m²) Mean (±SD) (min–max) | 18.3 (±2.8) (4.9–36.1) | 18.2 (±2.6) (11.7–26.6) | 18.4 (±3.0) (4.9–36.1) |
BMI, body mass index; FBM, fat body mass; LBM, lean body mass; MBM, muscle body mass; SFM, subcutaneous fat mass; VFM, visceral fat mass.